Metabolically healthy obesity: fact or fiction?

A session at this year’s Annual Meeting of the European Association for the Study of Diabetes will explore the latest data on the concept of metabolically healthy obesity (MHO) – more commonly known by the public as ‘fat but fit’. Professor Matthias Blüher, University of Leipzig, Leipzig and Helmholtz Center Munich, Germany  will explain how we define MHO and ask if it can really be described as healthy.

“Some 15-20% of people living with obesity have none of the metabolic complications we associate with the condition, namely abnormal blood sugar control and blood fats, high blood pressure, type 2 diabetes and other signs of cardiovascular disease,” explains Prof Blüher.

Estimates suggest a different prevalence of MHO in men and women, with women living with obesity more likely to have MHO (7-28%) than men (2-19%). At the other end of the spectrum, around half of people living with obesity have at least 2 complications. For a given total body fat mass, people with MHO have lower liver fat mass (thann expected for the BMI and total fat mass).

Prof Blüher will discuss that is how the adipose tissue behaves in people with obesity, rather than their body-mass index, that will determine whether or not their obesity is MHO. In people with adipocytes (fat storing cells) that are of a normal size, those people are less likely to display the complications of obesity – whereas in people with enlarged adipocytes and inflamed adipose tissue, these cells are more likely to exhibit traits such as insulin resistance that lead to metabolic complications.

And the way that we store fat is likely key in whether or not obesity can be described as MHO. “When people with obesity have fat stored viscerally, or internally around their organs (such as in the liver), the data show that these people are much more likely to develop type 2 diabetes than those who store fat more evenly around their body,” says Prof Blüher.

He goes on to explain that in people with adipose tissue dysfunction, this can lead to damaged tissue, fibrosis, secretion of proinflammatory and adipogenic molecules that subsequently contribute to end-organ damage. As an example, adipokines (fat released hormones) may act directly on cells of the vascular system and lead to atherosclerosis. In addition, metabolites such as fatty acids may impair the function of liver or insulin-producing cells in the pancreas.

Finally, on the key question as to whether or not MHO can genuinely be described as healthy, Prof Blüher will explain that several studies show that compared with people of normal weight with no metabolic comorbidities, people living with obesity with no metabolic comorbidities have a 50% increased risk of coronary heart disease. “So there is still a residual increased risk for those people living with obesity, even with what we would call metabolically healthy obesity,” he says.

In conclusion, there are people with obesity that do not exhibit cardio-metabolic complications at a certain point in time. In the past, the diagnosis of MHO frequently led to a low priority for obesity treatment. This concept has been challenged, because recent data suggest that the term metabolically healthy obesity is misleading. He concludes: “Even in the absence of other cardiometabolic risk factors, increased fat mass and adipose tissue dysfunction contribute to a higher risk of type 2 diabetes and cardiovascular diseases. Therefore, weight management and recommendations for weight loss are still important for people living with metabolically healthy obesity.”

This press release is based on session S24 to take place in the Hamburg Hall at the European Association for the Study of Diabetes (EASD) Annual Meeting in Hamburg at 0900H AM CEST on Wednesday 4 October. The presenter is happy to answer any questions.

Prof Blüher will also take part in the embargoed press conference taking place at 1200H Noon CEST Hamburg time on Tues 3 Oct, in the Vienna Hall.